PortViewPortView
Lycia Therapeutics logo

Lycia Therapeutics (LYCA) Stock Analysis

NASDAQHealthcareBiotechnology

$25.31-3.06%
1-year price historyRange $25.31 – $30.00
52-week range$25.31
$22.19$36.49

Track LYCA in your portfolio for free · Portfolio tracker

What Lycia Therapeutics does

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

Key metrics

Market cap
$1.32B
Beta
0.00
50-day avg
$28.32
200-day avg
$28.32
52-week high
$36.49
52-week low
$22.19
CEO
Aetna Wun Trombley

ETFs linked to LYCA

Broad-market and Healthcare sector ETFs an investor holding Lycia Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LYCA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze LYCA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Lycia Therapeutics?
Lycia Therapeutics trades under the ticker LYCA on NASDAQ.
Which exchange is LYCA listed on?
LYCA is listed on NASDAQ.
What sector does Lycia Therapeutics operate in?
Lycia Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze LYCA in a portfolio?
PortView shows LYCA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.